Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition

Fig. 5

Valproic acid/simvastatin combination potentiate docetaxel antitumor effect in prostate cancer models. a 22Rv1 cells were treated or untreated with VPA, SIM and DTX at the respective IC5096h doses for 48 and 72 h. Apoptotic effect was evaluated by flow cytometry as the percentage of hypodiploid population (sub-G0-G1). b Apoptosis was evaluated by Caspase 3/7 activity assay, in 22Rv1 cells untreated or treated as above and evaluated by luminescence assay. c Western blotting of γH2AX in 22Rv1 cells, untreated or treated as above; CDK4 serves as control for equal protein loading. d 22Rv1 cells (40,000 cells/mL) were seeded in sphere medium in low attachment 96 multiwell to form spheres D: cell seeded and concomitantly untreated or treated with VPA and SIM at the respective IC5096h, then disaggregated and plated again for 72 h in absence or presence of DTX at IC5096h doses. The spheroids were counted and the values are the means ± S. D from at least three independent experiments (Right panel: representative images from spheres D experiment in E). Statistically significant results are reported (*** indicates P < 0.0005, ** indicates P < 0.005 and * indicates P < 0.05)

Back to article page